Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and...

Anticancer research 2020 / 03 Vol. 40; Iss. 3

Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer

KIMURA, MICHIO, USAMI, EISEKI, TERAMACHI, HITOMI, YOSHIMURA, TOMOAKI
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
40
Journal:
Anticancer Research
DOI:
10.21873/anticanres.14108
Date:
March, 2020
File:
PDF, 143 KB
2020
Conversion to is in progress
Conversion to is failed